Cardiovascular function and treatment in β-thalassemia major: A consensus statement from the american heart association

Circulation

Volumn 128, Issue 3, 2013, Pages 281-308

  Pennell, Dudley J ^a   Udelson, James E ^a   Arai, Andrew E ^a   Bozkurt, Biykem ^a   Cohen, Alan R ^a   Galanello, Renzo ^a   Hoffman, Timothy M ^a   Kiernan, Michael S ^a   Lerakis, Stamatios ^a   Piga, Antonio ^a   Porter, John B ^a   Walker, John Malcolm ^a   Wood, John ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRITIN; HEMOGLOBIN; IRON; NIFEDIPINE;

ACUTE HEART FAILURE; AGE; ANEMIA; ARTICLE; AUGMENTATION INDEX; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CAUSE OF DEATH; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTRIC CONDUCTIVITY; ELECTROCARDIOGRAPHY; END STAGE LIVER DISEASE; ERYTHROPOIESIS; EXERCISE TEST; FERRITIN BLOOD LEVEL; HEART ARRHYTHMIA; HEART DEATH; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HEMOSIDEROSIS; HEART OUTPUT; HEART VENTRICLE FUNCTION; HEMOCHROMATOSIS; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; LIVER CELL CARCINOMA; MEDICAL SOCIETY; MONOTHERAPY; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREGNANCY; PRIORITY JOURNAL; PULSE WAVE; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKLE CELL ANEMIA; SIDEROBLASTIC ANEMIA; SUDDEN DEATH; SURVIVAL; TACHYCARDIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR;

AHA SCIENTIFIC STATEMENT; CT AND MRI; HEART FAILURE; OTHER HEART FAILURE; OTHER TREATMENT; THALASSEMIA;

AMERICAN HEART ASSOCIATION; BETA-THALASSEMIA; CONSENSUS; HEART FAILURE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; UNITED STATES;

EID: 84880327550     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e31829b2be6     Document Type: Article

References (330)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193.
2. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051-2052.
3. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M. Survival of medically treated thalassemia patients in Cyprus: trends and risk factors over the period 1980-2004. Haematologica. 2006;91:1187-1192.
4. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445-450.
5. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-2179.
6. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ. Cardiac T2 magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-1968.
7. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2 magnetic resonance and cardiac iron. Circulation. 2011;123:1519-1528.
8. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-3744.
9. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-1884.
10. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115:2364-2371.
11. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2 cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
12. Telfer P. Update on survival in thalassemia major. Hemoglobin. 2009;33(suppl 1):S76-S80.
13. Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Karagiorga-Lagana M. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging. 2011;34:56-59.
14. Au WY, Lee V, Lau CW, Yau J, Chan D, Chan EY, Cheung WW, Ha SY, Kho B, Lee CY, Li RC, Li CK, Lin SY, Ling AS, Mak V, Sun L, Wong KH, Wong R, Yuen HL. A synopsis of current care of thalassaemia major patients in Hong Kong. Hong Kong Med J. 2011;17:261-266.
15. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007;138:407-421.
16. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol. 2008;141:882-890.
17. Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A; Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown). 2008;9:515-525.
18. Aessopos A, Kati M, Tsironi M. Congestive heart failure and treatment in thalassemia major. Hemoglobin. 2008;32:63-73.
19. Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today: prediction, prevention and management. Eur J Haematol. 2008;80:93-106.
20. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011;124:2253-2263.
21. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92:583-588.
22. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104:34-39.
23. Aessopos A, Tsironi M, Andreopoulos A, Farmakis D. Heart disease in thalassemia intermedia. Hemoglobin. 2009;33(suppl 1):S170-S176.
24. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(suppl 1):S16-S19.
25. Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the current literature. Br J Haematol. 2012;157:664-673.
26. Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassemia. 2nd ed rev. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
27. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30:698-705.
28. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
29. Charafeddine K, Isma'eel H, Charafeddine M, Inati A, Koussa S, Naja M, Taher A. Survival and complications of beta-thalassemia in Lebanon: a decade's experience of centralized care. Acta Haematol. 2008;120:112-116.
30. Modell B. The management of the improved prognosis in thalassemia major. Birth Defects Orig Artic Ser. 1982;18:329-337.
31. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.
32. Ladis V, Chouliaras G, Berdoukas V, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Kattamis A, Karagiorga-Lagana M. Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol. 2011;86:332-338.
33. Au WY, Lam WW, Chu WW, Yuen HL, Ling AS, Li RC, Chan HM, Lee HK, Law MF, Liu HS, Liang R, Ha SY. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong. Haematologica. 2008;93: 784-786.
34. Aypar E, Alehan D, Hazirolan T, Gümrük F. The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2 cardiovascular magnetic resonance. Int J Cardiovasc Imaging. 2010;26:413-421.
35. Patton N, Brown G, Leung M, Bavishi K, Taylor J, Lloyd J, Lee SH, Tay L, Worthley S. Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion-dependent patients with beta thalassaemia: significant association between low cardiac T2 < 10 ms and cardiac events. Intern Med J. 2010;40:419-426.
36. Daar S, Pathare AV, Jain R, Zadjali SA, Pennell DJ. T2 cardiovascular magnetic resonance in the management of thalassemia patients in Oman. Haematologica. 2009;94:140-141.
37. Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood. 2012;119:2746-2753.
38. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543-547.
39. Positano V, Pepe A, Santarelli MF, Ramazzotti A, Meloni A, De Marchi D, Favilli B, Cracolici E, Midiri M, Spasiano A, Lombardi M, Landini L. Multislice multiecho T2 cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. NMR Biomed. 2009;22:707-715.
40. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M. Cardiac magnetic resonance imaging R2 assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica. 2007;92:131-132.
41. Carpenter JP, Roughton M, Pennell DJ. International survey of T2 cardiovascular magnetic resonance in thalassemia. Haematologica. 2012;97(e-suppl 1):248-249.
42. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
43. Marsella M, Borgna-Pignatti C, Meloni A, Caldarelli V, Dell'Amico MC, Spasiano A, Pitrolo L, Cracolici E, Valeri G, Positano V, Lombardi M, Pepe A. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2 magnetic resonance imaging study. Haematologica. 2011;96:515-520.
44. Engle MA. Cardiac involvement in Cooley's anemia. Ann N Y Acad Sci. 1964;119:694-702.
45. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(pt 1):540-545.
46. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med. 2001;111:349-354.
47. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2 cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-355.
48. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk betathalassemia. Blood. 2000;95:1229-1236.
49. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol. 2003;70:398-403.
50. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
51. Thomas AS, Garbowski M, Ang AL, Shah FT, Walker JM, Moon JC, Pennell DJ, Porter JB. A decade follow-up of a thalassemia major (TM) cohort monitored by cardiac magnetic resonance imaging (CMR): significant reduction in patients with cardiac iron and in total mortality. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 1011.
52. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G, Agus A, Angelucci E. Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica. 2008;93:1385-1388.
53. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936.
54. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica. 2008;93:917-920.
55. Fernandes JL, Fabron A Jr, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica. 2009;94:1776-1777.
56. Ludwiczek S, Theurl I, Muckenthaler MU, Jakab M, Mair SM, Theurl M, Kiss J, Paulmichl M, Hentze MW, Ritter M, Weiss G. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med. 2007;13:448-454.
57. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, Yazdanpanah M, Wilson GJ, Schwartz A, Liu PP, Backx PH. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187-1194.
58. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol. 2012;88:535-548.
59. Kumfu S, Chattipakorn S, Fucharoen S, Chattipakorn N. Ferric iron uptake into cardiomyocytes of ?-thalassemic mice is not through calcium channels. Drug Chem Toxicol. 2013;36:329-334.
60. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med. 1985;106: 147-153.
61. Fernandes JL, Sampaio EF, Fertrin K, Coelho OR, Loggetto S, Piga A, Verissimo M, Saad ST. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med. In press.
62. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115:106-108.
63. Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major. Hemoglobin. 2006;30:251-256.
64. Origa R, Satta S, Matta G, Galanello R. Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major. Br J Haematol. 2008;142:143-145.
65. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol. 2009;84:328-334.
66. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. J Card Fail. 2010;16:888-900.
67. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1-9.
68. Link G, Pinson A, Hershko C. Ability of the orally effective iron chelators dimethyl-and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood. 1994;83:2692-2697.
69. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the iron shuttle hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
70. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386-395.
71. Kim E, Giri SN, Pessah IN. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicol Appl Pharmacol. 1995;130:57-66.
72. Buja LM, Roberts WC. Iron in the heart: etiology and clinical significance. Am J Med. 1971;51:209-221.
73. Kirk P, Sheppard M, Carpenter J, Anderson L, He T, De Noronha S, St Pierre T, Galanello R, Catani G, Wood J, Fucharoen S, Porter J, Walker JM, Forni G, Pennell D. Fibrosis in cardiac siderosis: update on historical perspectives. Haematologica. 2012;97(e-Suppl 1):382.
74. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med. 2002;32:833-840.
75. Veglio F, Melchio R, Rabbia F, Molino P, Genova GC, Martini G, Schiavone D, Piga A, Chiandussi L. Blood pressure and heart rate in young thalassemia major patients. Am J Hypertens. 1998;11:539-547.
76. Li W, Coates T, Wood JC. Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major. Haematologica. 2008;93:311-312.
77. Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A, Forni G, Derchi G, Favilli B, Rossi G, Cracolici E, Midiri M, Lombardi M. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart. 2009;95:1688-1693.
78. Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:8.
79. Omura T, Yoshiyama M, Hayashi T, Nishiguchi S, Kaito M, Horiike S, Fukuda K, Inamoto S, Kitaura Y, Nakamura Y, Teragaki M, Tokuhisa T, Iwao H, Takeuchi K, Yoshikawa J. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res. 2005;96:148-150.
80. Trikas A, Tentolouris K, Katsimaklis G, Antoniou J, Stefanadis C, Toutouzas P. Exercise capacity in patients with beta-thalassemia major: relation to left ventricular and atrial size and function. Am Heart J. 1998;136:988-990.
81. Hamdy AM, Zein El-Abdin MY, Abdel-Hafez MA. Right ventricular function in patients with beta thalassemia: relation to serum ferritin level. Echocardiography. 2007;24:795-801.
82. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation. 2002;106:2561-2566.
83. Cheung YF, Chan GC, Ha SY. Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. Br J Haematol. 2008;141:728-733.
84. Kukongviriyapan V, Somparn N, Senggunprai L, Prawan A, Kukongviriyapan U, Jetsrisuparb A. Endothelial dysfunction and oxidant status in pediatric patients with hemoglobin E-beta thalassemia. Pediatr Cardiol. 2008;29:130-135.
85. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J. 2003;24:113-119.
86. Marcí M, Pitrolo L, Lo Pinto C, Sanfilippo N, Malizia R. Detection of early cardiac dysfunction in patients with beta thalassemia by tissue Doppler echocardiography. Echocardiography. 2011;28:175-180.
87. Westwood MA, Wonke B, Maceira AM, Prescott E, Walker JM, Porter JB, Pennell DJ. Left ventricular diastolic function compared with T2 cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. J Magn Reson Imaging. 2005;22:229-233.
88. Stakos DA, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Boudoulas H. Cardiovascular involvement in patients with beta-thalassemia major without cardiac iron overload. Int J Cardiol. 2009;134:207-211.
89. Mancuso L, Mancuso A, Bevacqua E, Rigano P. Electrocardiographic abnormalities in thalassemia patients with heart failure. Cardiovasc Hematol Disord Drug Targets. 2009;9:29-35.
90. Ramazzotti A, Pepe A, Positano V, Scattini B, Santarelli MF, Landini L, De Marchi D, Keilberg P, Derchi G, Formisano F, Pili M, Lai ME, Forni G, Filosa A, Prossomariti L, Capra M, Pitrolo L, Borgna-Pignatti C, Cianciulli P, Maggio A, Lombardi M. Standardized T2 map of a normal human heart to correct T2 segmental artefacts: myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients. Hemoglobin. 2008;32:97-107.
91. Detterich J, Noetzli L, Dorey F, Bar-Cohen Y, Harmatz P, Coates T, Wood J. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol. 2012;87:139-144.
92. Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major. Am Heart J. 2010;159:68-74.
93. Delaporta P, Kattamis A, Apostolakou F, Boiu S, Bartzeliotou A, Tsoukas E, Papassotiriou I. Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major. Blood Cells Mol Dis. 2013;50:20-24.
94. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21:1387-1396.
95. Giakoumis A, Berdoukas V, Gotsis E, Aessopos A. Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance (CMR) imaging in transfusion dependent thalassemia major (TM). Cardiovasc Ultrasound. 2007;5:24.
96. Hahalis G, Kourakli A, Gerasimidou I, Kalogeropoulos AP, Sitafidis G, Papageorgiou U, Davlouros P, Grapsas N, Zoumbos NC, Alexopoulos D. Cardiac mortality in {beta}-thalassemia major: resting but not dobutamine stress echocardiography predicts mortality among initially cardiac disease-free patients in a prospective 12-year study. Eur J Heart Fail. 2009;11:1178-1181.
97. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
98. Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ Jr, Griffith P, Nienhuis AW. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N Engl J Med. 1979;301:1143-1148.
99. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417-426.
100. Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J. 2006;27:2879-2888.
101. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:29-34.
102. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004;147:218-223.
103. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, Wonke B, Walker JM, Pennell DJ. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007;25:1147-1151.
104. Carpenter JP, Alpendurada F, Deac M, Maceira A, Garbowski M, Kirk P, Walker JM, Porter JB, Shah F, Banya W, He T, Smith GC, Pennell DJ. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. J Cardiovasc Magn Reson. 2010;12:24.
105. Fernandes JL, Silveira MA, Fertrin K, Lauar S, Fattori A, Coelho O, Junqueira FP, da Cunha GM, Coutinho AC Jr, Pereira FB, Verissimo M, Saad ST. Left and right ventricular function and volume assessment in young thalassemia major patients with no related myocardial iron overload. Ann Hematol. 2012;91:1839-1844.
106. Meloni A, Detterich J, Berdoukas V, Pepe A, Lombardi M, Coates TD, Wood JC. Comparison of biventricular dimensions and function between pediatric sickle-cell disease and thalassemia major patients without cardiac iron. Am J Hematol. 2013;88:213-218.
107. Roghi A, Dellegrottaglie S, Pedrotti P, Pedretti S, Cassinerio E, Cappellini MD. Unexpected myocarditis in thalassaemia major patient screened for iron load cardiomyopathy. BMJ Case Rep. 2009;2009:bcr08.2008.0811.
108. Rathi VK, Doyle M, Yamrozik J, Williams RB, Caruppannan K, Truman C, Vido D, Biederman RW. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: a practical approach. J Cardiovasc Magn Reson. 2008;10:36.
109. Plein S, Schulz-Menger J, Almeida A, Mahrholdt H, Rademakers F, Pennell D, Nagel E, Schwitter J, Lombardi M; Working Group on Cardiovascular Magnetic Resonance, European Society of Cardiology. Training and accreditation in cardiovascular magnetic resonance in Europe: a position statement of the working group on cardiovascular magnetic resonance of the European Society of Cardiology. Eur Heart J. 2011;32:793-798.
110. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, Society for Cardiovascular Magnetic Resonance: Board of Trustees Task Force on Standardized Protocols. J Cardiovasc Magn Reson. 2008;10:35.
111. Maffei E, Messalli G, Martini C, Nieman K, Catalano O, Rossi A, Seitun S, Guaricci AI, Tedeschi C, Mollet NR, Cademartiri F. Left and right ventricle assessment with cardiac CT: validation study vs. cardiac MR. Eur Radiol. 2012;22:1041-1049.
112. Wood JC, Mo A, Gera A, Koh M, Coates T, Gilsanz V. Quantitative computed tomography assessment of transfusional iron overload. Br J Haematol. 2011;153:780-785.
113. Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, Pennell DJ. Interscanner reproducibility of cardiovascular magnetic resonance T2 measurements of tissue iron in thalassemia. J Magn Reson Imaging. 2003;18:616-620.
114. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, Vasili B, Pennell DJ. Intercentre reproducibility of magnetic resonance T2 measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging. 2005;21:531-538.
115. Kirk P, He T, Anderson LJ, Roughton M, Tanner MA, Lam WW, Au WY, Chu WC, Chan G, Galanello R, Matta G, Fogel M, Cohen AR, Tan RS, Chen K, Ng I, Lai A, Fucharoen S, Laothamata J, Chuncharunee S, Jongjirasiri S, Firmin DN, Smith GC, Pennell DJ. International reproducibility of single breathhold T2 MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32:315-319.
116. Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res. 1980;14:719-724.
117. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ. Relation of myocardial T2 to right ventricular function in thalassaemia major. Eur Heart J. 2010;31:1648-1654.
118. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ. A single breath-hold multiecho T2 cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging. 2003;18:33-39.
119. He T, Gatehouse PD, Kirk P, Tanner MA, Smith GC, Keegan J, Mohiaddin RH, Pennell DJ, Firmin DN. Black-blood T2 technique for myocardial iron measurement in thalassemia. J Magn Reson Imaging. 2007;25:1205-1209.
120. Smith GC, Carpenter JP, He T, Alam MH, Firmin DN, Pennell DJ. Value of black blood T2 cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:21.
121. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2 cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging. 2006;23:662-668.
122. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC. Improved R2 measurements in myocardial iron overload. J Magn Reson Imaging. 2006;23:9-16.
123. Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD Jr, Coates TD, Wood JC. MRI detects myocardial iron in the human heart. Magn Reson Med. 2006;56:681-686.
124. Wood JC, Noetzli L. Cardiovascular MRI in thalassemia major. Ann N Y Acad Sci. 2010;1202:173-179.
125. Storey P, Thompson AA, Carqueville CL, Wood JC, de Freitas RA, Rigsby CK. R2 imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007;25:540-547.
126. Meloni A, Positano V, Keilberg P, De Marchi D, Pepe P, Zuccarelli A, Campisi S, Romeo MA, Casini T, Bitti PP, Gerardi C, Lai ME, Piraino B, Giuffrida G, Secchi G, Midiri M, Lombardi M, Pepe A. Feasibility, reproducibility, and reliability for the T.2 iron evaluation at 3 T in comparison with 1.5 T. Magn Reson Med. 2012;68:543-551.
127. Hider RC, Liu ZD. Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload. Curr Med Chem. 2003;10:1051-1064.
128. Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos. 1993;21:640-644.
129. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314:869-873.
130. Kwiatkowski JL. Management of transfusional iron overload: differential properties and efficacy of iron chelating agents. J Blood Med. 2011;2:135-149.
131. Adamkiewicz TV, Berkovitch M, Krishnan C, Polsinelli C, Kermack D, Olivieri NF. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis. 1998;27:1362-1366.
132. Chan GC, Chan S, Ho PL, Ha SY. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin. 2009;33:352-360.
133. Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. Am J Dis Child. 1990;144:565-569.
134. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol. 2009;122:155-164.
135. al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403-408.
136. Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012;8:123-134.
137. Nick H. Deferasirox (Exjade, ICL670) preclinical overview. Semin Hematol 2007;44(suppl 3):S12-S15.
138. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154:387-397.
139. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman
140. Exjade (deferasirox) US Prescribing Information. T2013-04. January 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021882s 010lbl.pdf. Accessed May 23, 2013.
141. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association (HFA) of the ESC [published correction appears in Eur J Heart Fail. 2013;15:361-362]. Eur J Heart Fail. 2012;14:803-869.
142. Forni GL, Derchi G. Typical manifestation of acute congestive heart failure in patients with Thalassaemia major causing diagnostic delay in the emergency room. Eur J Heart Fail. 2003;5:607-608.
143. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-977.
144. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-573.
145. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632-4639.
146. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
147. Liu Y, Parkes JG, Templeton DM. Differential accumulation of nontransferrin-bound iron by cardiac myocytes and fibroblasts. J Mol Cell Cardiol. 2003;35:505-514.
148. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112:2973-2978.
149. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R. Cardiac iron determines cardiac T2, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-543.
150. Collins W, Taylor WH. Determination of iron in cardiac and liver tissues by plasma emission spectroscopy. Ann Clin Biochem. 1987;24(pt 5):483-487.
151. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263-269.
152. Seldrum S, Pierard S, Moniotte S, Vermeylen C, Vancraeynest D, Pasquet A, Vanoverschelde JL, Gerber BL. Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging. J Cardiovasc Magn Reson. 2011;13:23.
153. Efthimiadis GK, Hassapopoulou HP, Tsikaderis DD, Karvounis HI, Giannakoulas GA, Parharidis GE, Louridas GE. Survival in thalassaemia major patients. Circ J. 2006;70:1037-1042.
154. Nanas S, Vasileiadis I, Dimopoulos S, Sakellariou D, Kapsimalakou S, Papazachou O, Tasoulis A, Ladis V, Pangalis G, Aessopos A. New insights into the exercise intolerance of beta-thalassemia major patients. Scand J Med Sci Sports. 2009;19:96-102.
155. Mavrogeni S, Gotsis E, Verganelakis D, Berdousis E, Dritsas A, Kolovou G, Toulas P, Ladis V. Effect of iron overload on exercise capacity in thalassemic patients with heart failure. Int J Cardiovasc Imaging. 2009;25:777-783.
156. Tocco F, Crisafulli A, Melis F, Loviselli A, Lai C, Concu A. Exercise capacity and cardiovascular changes in patients with beta-thalassaemia major. Clin Physiol Funct Imaging. 2006;26:319-322.
157. Vasileiadis I, Roditis P, Dimopoulos S, Ladis V, Pangalis G, Aessopos A, Nanas S. Impaired oxygen kinetics in beta-thalassaemia major patients. Acta Physiol (Oxf). 2009;196:357-363.
158. Sohn EY, Kato R, Noetzli LJ, Gera A, Coates T, Harmatz P, Keens TG, Wood JC. Exercise performance in thalassemia major: correlation with cardiac iron burden. Am J Hematol. 2013;88:193-197.
159. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-2442.
160. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119:1977-2016.
161. Heart Failure Society of America; Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-e194.
162. Rosenthal D, Chrisant MR, Edens E, Mahony L, Canter C, Colan S, Dubin A, Lamour J, Ross R, Shaddy R, Addonizio L, Beerman L, Berger S, Bernstein D, Blume E, Boucek M, Checchia P, Dipchand A, Drummond-Webb J, Fricker J, Friedman R, Hallowell S, Jaquiss R, Mital S, Pahl E, Pearce FB, Pearce B, Rhodes L, Rotondo K, Rusconi P, Scheel J, Pal Singh T, Towbin J. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children [published correction appears in J Heart Lung Transplant. 2009;28:987]. J Heart Lung Transplant. 2004;23:1313-1333.
163. Malcom J, Arnold O, Howlett JG, Ducharme A, Ezekowitz JA, Gardner M, Giannetti N, Haddad H, Heckman GA, Isaac D, Jong P, Liu P, Mann E, McKelvie RS, Moe GW, Svendsen AM, Tsuyuki RT, O'Halloran K, Ross HJ, Sequeira EJ, White M; Canadian Cardiovascular Society. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure-2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol. 2008;24:21-40.
164. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2005;112:e154-e235.
165. Kremastinos DT. Heart failure in beta-thalassaemia: a local or universal health problem? Hellenic J Cardiol. 2007;48:189-190.
166. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114:4021-4026.
167. Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci. 2010;1202:123-128.
168. Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypoparathyroidism and heart failure in thalassemic patients: a case report. Pediatr Endocrinol Rev. 2004;2(suppl 2):310-312.
169. Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypocalcemic heart failure in thalassemic patients. Int J Hematol. 2006;83:314-317.
170. De Sanctis V, Borsari G, Brachi S, Gubellini E, Gamberini MR, Carandina G. A rare cause of heart failure in iron-overload thalassaemic patientsprimary hypoparathyroidism. Georgian Med News 2008;(156):111-113.
171. De Sanctis V, Govoni MR, Sprocati M, Marsella M, Conti E. Cardiomyopathy and pericardial effusion in a 7 year-old boy with betathalassaemia major, severe primary hypothyroidism and hypoparathyroidism due to iron overload. Pediatr Endocrinol Rev. 2008;6(suppl 1):181-184.
172. De Sanctis V, De Sanctis E, Ricchieri P, Gubellini E, Gilli G, Gamberini MR. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study. Pediatr Endocrinol Rev. 2008;6(suppl 1):174-180.
173. Banani SA, Omrani GH. Cortisol and adrenocorticotropic hormone response to surgical stress (splenectomy) in thalassemic patients. Pediatr Surg Int. 2000;16:400-403.
174. Drakonaki E, Papakonstantinou O, Maris T, Vasiliadou A, Papadakis A, Gourtsoyiannis N. Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores. Eur Radiol. 2005;15:2462-2468.
175. Jaruratanasirikul S, Tanchotikul S, Wongcharnchailert M, Laosombat V, Sangsupavanich P, Leetanaporn K. A low dose adrenocorticotropin test (1 microg ACTH) for the evaluation of adrenal function in children with beta-thalassemia receiving hypertransfusion with suboptimal iron-chelating therapy. J Pediatr Endocrinol Metab. 2007;20:1183-1188.
176. Poomthavorn P, Isaradisaikul B, Chuansumrit A, Khlairit P, Sriphrapradang A, Mahachoklertwattana P. High prevalence of biochemical adrenal insufficiency in thalassemics: is it a matter of different testings or decreased cortisol binding globulin? J Clin Endocrinol Metab. 2010;95:4609-4615.
177. Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Radaelli P, Ambrogio A, D'Angelo E, Mirra N, Zanaboni L, Cappellini MD, Cavagnini F. The pituitary-adrenal axis in adult thalassaemic patients. Eur J Endocrinol. 2010;162:43-48.
178. Srivatsa A, Marwaha RK, Muraldharan R, Trehan A. Assessment of adrenal endocrine function in Asian thalassemics. Indian Pediatr. 2005;42:31-35.
179. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Lane J, Schneider R, Fleisher M, Grady RW, Peterson CC, Giardina PJ; Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24:543-557.
180. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919-927.
181. Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: treatment implications. Curr Heart Fail Rep. 2010;7:59-65.
182. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy: fact or fiction? Herz. 2011;36:102-115.
183. Claster S, Wood JC, Noetzli L, Carson SM, Hofstra TC, Khanna R, Coates TD. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol. 2009;84:344-348.
184. Chiou SS, Chang TT, Tsai SP, Jang RC, Lin SK, Lee SC, Tsai SM, Tsai LY. Lipid peroxidation and antioxidative status in beta-thalassemia major patients with or without hepatitis C virus infection. Clin Chem Lab Med. 2006;44:1226-1233.
185. Kassab-Chekir A, Laradi S, Ferchichi S, Haj Khelil A, Feki M, Amri F, Selmi H, Bejaoui M, Miled A. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta. 2003;338:79-86.
186. Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, D'Arpa D, D'Anna R, Bongiorno A. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood. 1996;88:3608-3614.
187. Bartfay WJ, Bartfay E. Selenium and glutathione peroxidase with betathalassemia major. Nurs Res. 2001;50:178-183.
188. El-Beshlawy A, El Accaoui R, Abd El-Sattar M, Gamal El-Deen MH, Youssry I, Shaheen N, Hamdy M, El-Ghamrawy M, Taher A. Effect of L-carnitine on the physical fitness of thalassemic patients. Ann Hematol. 2007;86:31-34.
189. El-Beshlawy A, Ragab L, Fattah AA, Ibrahim IY, Hamdy M, Makhlouf A, Aoun E, Hoffbrand V, Taher A. Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol. 2004;111:143-148.
190. Wood JC, Claster S, Carson S, Menteer JD, Hofstra T, Khanna R, Coates T. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol. 2008;141:891-894.
191. Otto-Duessel M, Brewer C, Wood JC. Interdependence of cardiac iron and calcium in a murine model of iron overload. Transl Res. 2011;157:92-99.
192. Noetzli LJ, Carson S, Coates TD, Wood JC. Revisiting the relationship between vitamin D deficiency, cardiac iron and cardiac function in thalassemia major. Eur J Haematol. 2011;86:176-177.
193. Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, Goldfarb A. Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol. 2006;133:667-674.
194. Bozdogan G, Erdem E, Demirel GY, Yildirmak Y. The role of Treg cells and FoxP3 expression in immunity of ?-thalassemia major and ?-thalassemia trait patients. Pediatr Hematol Oncol. 2010;27:534-545.
195. Gharagozloo M, Karimi M, Amirghofran Z. Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity. Ann Hematol. 2009;88:21-27.
196. Pardalos G, Kanakoudi-Tsakalidis F, Malaka-Zafiriu M, Tsantali H, Athanasiou-Metaxa M, Kallinikos G, Papaevangelou G. Iron-related disturbances of cell-mediated immunity in multitransfused children with thalassemia major. Clin Exp Immunol. 1987;68:138-145.
197. Kanakoudi-Tsakalidis F, Spyroglou K, Tzafi R, Cassimos C. Effect of blood transfusion on the immune response of children with thalassaemia. Acta Haematol. 1977;57:65-73.
198. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in beta-thalassemia major: a cause of heart failure. Circulation. 1995;91:66-71.
199. Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D, Stavropoulos-Giokas CG. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. Circulation. 1999;100:2074-2078.
200. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73:359-366.
201. Jessup M, Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia. Ann N Y Acad Sci. 1998;850:242-250.
202. Vyssoulis G, Karpanou E, Kyvelou SM, Tzamou V, Theodosiadis G, Stefanadis C. Ambulatory blood pressure profile in anemic hypertensive patients. Int J Cardiol. 2010;145:301-302.
203. Cheung YF, Chow PC, Chan GC, Ha SY. Carotid intima-media thickness is increased and related to arterial stiffening in patients with beta-thalassaemia major. Br J Haematol. 2006;135:732-734.
204. Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, Kourakli A, Adamopoulos S, Tselepis AD, Grapsas N, Siablis D, Zoumbos NC, Alexopoulos D. Global vasomotor dysfunction and accelerated vascular aging in betathalassemia major. Atherosclerosis. 2008;198:448-457.
205. Stakos DA, Tavridou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. Eur J Haematol. 2009;82:477-483.
206. Cheung YF, Ha SY, Chan GC. Ventriculo-vascular interactions in patients with beta thalassaemia major. Heart. 2005;91:769-773.
207. Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsante E, Pitscheider W, Vaccari M. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart. 2003;89:762-766.
208. Lekawanvijit S, Chattipakorn N. Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol. 2009;25: 213-218.
209. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411-3416.
210. Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation. 1967;35:631-637.
211. Hidalgo C, Aracena P, Sanchez G, Donoso P. Redox regulation of calcium release in skeletal and cardiac muscle. Biol Res. 2002;35:183-193.
212. Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes: implications for the arrhythmogenesis of human siderotic heart disease. Circulation. 1999;100:675-683.
213. Rose RA, Sellan M, Simpson JA, Izaddoustdar F, Cifelli C, Panama BK, Davis M, Zhao D, Markhani M, Murphy GG, Striessnig J, Liu PP, Heximer SP, Backx PH. Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:733-742.
214. Kaye SB, Owen M. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. Br Med J. 1978;1:342.
215. Mariotti S, Loviselli A, Murenu S, Sau F, Valentino L, Mandas A, Vacquer S, Martino E, Balestrieri A, Lai ME. High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment. J Endocrinol Invest. 1999;22:55-63.
216. Russo V, Rago A, Pannone B, Papa AA, Di Meo F, Mayer MC, Spasiano A, Russo MG, Golino P, Calabrò R, Nigro G. Dispersion of repolarization and beta-thalassemia major: the prognostic role of QT and JT dispersion for identifying the high-risk patients for sudden death. Eur J Haematol. 2011;86:324-331.
217. Isma'eel H, Shamseddeen W, Taher A, Gharzuddine W, Dimassi A, Alam S, Masri L, Khoury M. Ventricular late potentials among thalassemia patients. Int J Cardiol. 2009;132:453-455.
218. Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F; for the Thalassemia Clinical Research Network. Treatment of heart failure in adults with thalassaemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013;15:38.
219. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15:329-368.
220. Forni GL, Puntoni M, Boeri E, Terenzani L, Balocco M. The influence of treatment in specialized centers on survival of patients with thalassemia major. Am J Hematol. 2009;84:317-318.
221. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol. 2005;74:84-85.
222. Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, Usai B, Matta G, Galanello R. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail. 2007;9:320-322.
223. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 2007;109:362-364.
224. Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica. 2006;91(suppl):ECR19.
225. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol. 2004;83:471-473.
226. Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 2010;45:136-139.
227. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure [published correction appears in J Am Coll Cardiol. 2007;49:1136]. J Am Coll Cardiol. 2007;49:675-683.
228. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59:2145-2153.
229. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296-2304.
230. Puskarich MA, Runyon MS, Trzeciak S, Kline JA, Jones AE. Effect of glucose-insulin-potassium infusion on mortality in critical care settings: a systematic review and meta-analysis. J Clin Pharmacol. 2009;49:758-767.
231. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009;53:1475-1487.
232. Olivieri NF, Liu PP, Sher GD, Daly PA, Greig PD, McCusker PJ, Collins AF, Francombe WH, Templeton DM, Butany J. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. N Engl J Med. 1994;330:1125-1127.
233. Perrimond H, Michel G, Orsini A, Kreitmann B, Metras D. First report of a cardiac transplantation in a patient with thalassaemia major. Br J Haematol. 1991;78:467.
234. Koerner MM, Tenderich G, Minami K, zu Knyphausen E, Mannebach H, Kleesiek K, Meyer H, Koerfer R. Heart transplantation for end-stage heart failure caused by iron overload. Br J Haematol. 1997;97:293-296.
235. Caines AE, Kpodonu J, Massad MG, Chaer R, Evans A, Lee JC, Geha AS. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant. 2005;24:486-488.
236. Short EM, Winkle RA, Billingham ME. Myocardial involvement in idiopathic hemochromatosis: morphologic and clinical improvement following venesection. Am J Med. 1981;70:1275-1279.
237. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91-96.
238. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica. 2011;96:1055-1058.
239. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116:537-543.
240. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360:516-520.
241. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88:705-713.
242. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol. 2009;147:744-751.
243. Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini MD. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol. 2009;84:29-33.
244. Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev. 2009;23(suppl 1):S3-S7.
245. Kwiatkowski JL. Oral iron chelators. Hematol Oncol Clin North Am. 2010;24:229-248.
246. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364:146-156.
247. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, De Marchi D, Midiri M, Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2. Eur J Haematol. 2006;76:183-192.
248. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96:41-47.
249. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
250. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733-3737.
251. Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2. Hemoglobin. 2009;33:323-331.
252. Ha SY, Mok AS, Chu WC, Rasalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC. Intermediate-term evaluation of a practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2. Hemoglobin. 2011;35:199-205.
253. European Medicines Agency Web site. Summary of product characteristics for Ferriprox. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000236/WC500022050. pdf. Accessed May 23, 2013.
254. Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Westwood MA, Galanello R, Roughton M, Pennell DJ. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson. 2011;13:34.
255. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Continued improvement in myocardial T2 over two years of deferasirox therapy in ?-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96:48-54.
256. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with ?-thalassemia major. Haematologica. 2012;97:842-848.
257. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol. 2010;85: 818-819.
258. Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2 in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010;89:405-409.
259. Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Beloul K, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y. A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with ?-thalassemia major and iron overload (CORDELIA). Blood (ASH Annual Meeting Abstracts). 2012;120:Abstract 2124.
260. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
261. Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88:1423-1425.
262. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res. 2010;156:55-67.
263. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148:466-475.
264. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J Pediatr Hematol Oncol. 2010;32:400-403.
265. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011;47:33-40.
266. Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson. 2012;14:8.
267. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
268. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009;94:1777-1778.
269. Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann N Y Acad Sci. 2010;1202:79-86.
270. Berdoukas V, Carson S, Nord A, Dongelyan A, Gavin S, Hofstra TC, Wood JC, Coates T. Combining two orally active iron chelators for thalassemia. Ann Hematol. 2010;89:1177-1178.
271. Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, Kurio G, Harmatz P, Vichinsky E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013;50: 99-104.
272. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009;145:245-254.
273. Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in
274. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major [published correction appears in N Engl J Med. 2000;343:1740]. N Engl J Med. 2000;343:327-331.
275. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, Sodani P, Tomassoni S, Visani G, Lucarelli G. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17-21.
276. Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C, Campisi S, Cianciulli P, Rizzo M, D'Ascola G, Ciancio A, Di Maggio R, Calvaruso G, Pantalone GR, Rigano P. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. Am J Hematol. 2012;87:732-733.
277. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed). 1982;284:1081-1084.
278. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, Del Vecchio GC, Magnano C, Meo A, Maggio A. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Haematologica. 2006;91:1420-1421.
279. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42:247-251.
280. Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. Obstet Gynecol Surv. 1994;49:129-137.
281. Tuck SM, Jensen CE, Wonke B, Yardumian A. Pregnancy management and outcomes in women with thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(suppl 3):923-928.
282. Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev. 2007;5:642-648.
283. Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, Galanello R. Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica. 2010;95:376-381.
284. Ansari S, Azarkeivan A, Kivan AA, Tabaroki A. Pregnancy in patients treated for beta thalassemia major in two centers (Ali Asghar Children's Hospital and Thalassemia Clinic): outcome for mothers and newborn infants [published correction appears in Pediatr Hematol Oncol. 2008;25:163]. Pediatr Hematol Oncol. 2006;23:33-37.
285. Bajoria R, Chatterjee R. Current perspectives of fertility and pregnancy in thalassemia. Hemoglobin. 2009;33(suppl 1):S131-S135.
286. Singer ST, Sweeters N, Vega O, Higa A, Vichinsky E, Cedars M. Fertility potential in thalassemia major women: current findings and future diagnostic tools. Ann N Y Acad Sci. 2010;1202:226-230.
287. Leung TY, Lao TT. Thalassaemia in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2012;26:37-51.
288. Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab. 1998;11(suppl 3):935-943.
289. Nassar AH, Usta IM, Rechdan JB, Koussa S, Inati A, Taher AT. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol. 2006;81:499-502.
290. Borgna-Pignatti C. Surviving with thalassemia major: the Italian experience. Pediatr Hematol Oncol. 2007;24:75-78.
291. Schwartz KA, Li Z, Schwartz DE, Cooper TG, Braselton WE. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol. 2002;93:746-751.
292. Ghader FR, Kousarian M, Farzin D. High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications. East Mediterr Health J. 2007;13:1053-1059.
293. Lombardo T, Ferro G, Frontini V, Percolla S. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. Am J Hematol. 1996;51: 90-92.
294. Fogel RI, Prystowsky EN. Management of malignant ventricular arrhythmias and cardiac arrest. Crit Care Med. 2000;28(suppl):N165-N169.
295. Ho KM. Intravenous magnesium for cardiac arrhythmias: jack of all trades. Magnes Res. 2008;21:65-68.
296. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart. 2007;93:1433-1440.
297. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139:3-13.
298. Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, Siritanaratkul N, Fucharoen S. Activated platelet-derived microparticles in thalassaemia. Br J Haematol. 2007;136:462-471.
299. Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, Abramov A, MacLouf J, Godefray YC, De Raucourt E, Guillin MC. A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br J Haematol. 1999;107:739-746.
300. Nault I, Miyazaki S, Forclaz A, Wright M, Jadidi A, Jaïs P, Hocini M, Haïssaguerre M. Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. Eur Heart J. 2010;31:1046-1054.
301. Pappone C, Santinelli V. Atrial fibrillation ablation: state of the art. Am J Cardiol. 2005;96(12A):59L-64L.
302. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, Engle MA. Longitudinal study of cardiac function in thalassemia major. Ann N Y Acad Sci. 1980;344:397-404.
303. Wilkoff BL, Bello D, Taborsky M, Vymazal J, Kanal E, Heuer H, Hecking K, Johnson WB, Young W, Ramza B, Akhtar N, Kuepper B, Hunold P, Luechinger R, Puererfellner H, Duru F, Gotte MJ, Sutton R, Sommer T; EnRhythm MRI SureScan Pacing System Study Investigators. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. Heart Rhythm. 2011;8:65-73.
304. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L, Filosa A, Rund D, Gamberini MR, Cianciulli P, De Montalembert M, Gagliardotto F, Foster G, Grangè JD, Cassarà F, Iacono A, Cappellini MD, Brittenham GM, Prati D, Pietrangelo A, Craxì A, Maggio A; Italian Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116:2875-2883.
305. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang. 2011;100:92-98.
306. Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with b thalassemia major: a single-institution fifteen-year experience. Haematologica. 2005;90:1136-1138.
307. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114-117.
308. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30:119-124.
309. Restivo Pantalone G, Renda D, Valenza F, D'Amato F, Vitrano A, Cassarà F, Rigano P, Di Salvo V, Giangreco A, Bevacqua E, Maggio A. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150:245-247.
310. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin. 2010;34:221-226.
311. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-2081.
312. Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, Petrarat S, Assateerawatt A, Vongjirad A. Renal tubular function in beta-thalassemia. Pediatr Nephrol. 1998;12:280-283.
313. Aldudak B, Karabay Bayazit A, Noyan A, Ozel A, Anarat A, Sasmaz I, Kilinç Y, Gali E, Anarat R, Dikmen N. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol. 2000;15:109-112.
314. Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, Koren A. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008;23:1847-1851.
315. Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ; Thalassemia Clinical Research Network. Renal dysfunction in patients with thalassaemia. Br J Haematol. 2011;153:111-117.
316. Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur J Haematol. 2012;89:187-197.
317. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev. 1999;31:971-997.
318. Ueda N. Oxidant mechanisms in acute renal failure. In Molitoris B, Finn W, eds. Acute Renal Failure: A Companion to Brenner & Rector's The Kidney. Philadelphia, PA: WB Saunders; 2001:60-77.
319. Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child. 1989;143:1077-1080.
320. Cianciulli P, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, Taccone Gallucci M, Casciani CU. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haematologica. 1992;77:514-515.
321. Cianciulli P, Sollecito D, Sorrentino F, Forte L, Gilardi E, Massa A, Papa G, Carta S. Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy. Kidney Int. 1994;46:467-470.
322. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias. Haematologica. 2010;95:557-566.
323. Brosnahan G, Gokden N, Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant. 2008;23:3356-3358.
324. Papadopoulos N, Vasiliki A, Aloizos G, Tapinis P, Kikilas A. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother. 2010;44:219-221.
325. Vlachaki E, Chatzinikolaou K, Bekiari E, Klonizakis F, Tsapas A. Is deferasirox implicated in multiple organ failure in a patient with homozygous ?-thalassemia? Angiology. 2011;62:346-348.
326. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56:674-676.
327. Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H. Acquired proximal renal tubular dysfunction in ?-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32:564-567.
328. Jensen JH, Tang H, Tosti CL, Swaminathan SV, Nunez A, Hultman K, Szulc KU, Wu EX, Kim D, Sheth S, Brown TR, Brittenham GM. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med. 2010;63:1201-1209.
329. Carpenter JP, Grasso AE, Porter JB, Shah F, Dooley J, Pennell DJ. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson. 2013;15:24.
330. Amlodipine use in the prevention and treatment of iron overload in patients with thalassemia major (AnloThal). http://www.clinicaltrials. gov/show/NCT01395199. May 23, 2013.